IMARC Group’s latest report, titled “Biomarker Technologies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the biomarker technologies market size. The report also includes competitor and regional analysis, and contemporary advancements in the market. The global biomarker technologies market size reached US$ 35.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 75.9 Billion by 2028, exhibiting a growth rate (CAGR) of 13.31% during 2023-2028. Biomarker Technologies Market Overview: Biomarker technologies are scientific tools utilized in medical and biological research to indicate the presence or severity of disease or evaluate treatment’s effect. These technologies include advanced methods of detecting, measuring, and analyzing biological substances such as genes, proteins, metabolites, or antibodies that serve as biomarkers. Biomarkers themselves are biological measures of a biological state. From a clinical perspective, they are crucial in disease diagnosis, prognostic assessment, therapeutic targeting, and drug response monitoring. In the arena of research and development, biomarker technologies are extensively utilized in drug discovery and development, personalized medicine, and disease risk assessment. With the advancements in molecular biology, genomics, and bioinformatics, these technologies are gaining traction in various fields, including oncology, neurology, cardiology, and more, thereby playing a critical role in advancing global health and personalized medicine. Request a Sample Report: https://www.imarcgroup.com/biomarker-technologies-market/requestsample Competitive Landscape with Key Players: The competitive landscape of the industry has also been examined along with the profiles of the key players being
- Agilent Technologies Inc
- Bio-Rad Laboratories Inc
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Illumina Inc
- LI-COR Inc
- Merck KGaA
- PerkinElmer Inc
- QIAGEN N.V
- Shimadzu Corporation
- Thermo Fisher Scientific Inc
- Waters Corporation
- Solid Biopsy
- Liquid Biopsy
- Cancer
- Infectious Diseases
- Autoimmune Disorders
- Cardiovascular Disorders
- Others
- Consumables
- Assay
- Reagent
- Instruments
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Immunoassay
- Others
- Drug Discovery
- Clinical Diagnostics
- Personalized Medicine
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape